Elixir Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 502.01%
(FY 2022)
- Profit 87.58%
(FY 2022)
- Ebitda 99.05%
(FY 2022)
- Net Worth 19.86%
(FY 2022)
- Total Assets 54.57%
(FY 2022)
About Elixir Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vishal Agarwal and Prashant Agarwal serve as directors at the Company.
- CIN/LLPIN
U85100HR2020PTC087947
- Company No.
087947
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Elixir Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Agarwal  | Director | 29-Jul-2020 | Current |
| Prashant Agarwal | Director | 29-Jul-2020 | Current |
Financial Performance of Elixir Pharmaceuticals.
Elixir Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 502.01% increase. The company also saw a substantial improvement in profitability, with a 87.58% increase in profit. The company's net worth Soared by an impressive increase of 19.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elixir Pharmaceuticals?
In 2022, Elixir Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zodiac Surgical & Medicine Private LimitedActive 8 years 11 monthsVishal Agarwal and Prashant Agarwal are mutual person
- Luxmisairam Foods Private LimitedActive 11 years 10 months
Vishal Agarwal and Prashant Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elixir Pharmaceuticals?
Elixir Pharmaceuticals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elixir Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elixir Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
